| Literature DB >> 28570559 |
Kei-Ichi Takata1, Shelley Reh1, Matthew J Yousefzadeh1,2, Maciej J Zelazowski1, Sarita Bhetawal1, David Trono1, Megan G Lowery1, Maria Sandoval1, Yoko Takata1, Yue Lu1, Kevin Lin1, Jianjun Shen1,2, Donna F Kusewitt1, Kevin M McBride1,2, Francesca Cole1,2, Richard D Wood1,2.
Abstract
DNA polymerase ν (pol ν), encoded by the POLN gene, is an A-family DNA polymerase in vertebrates and some other animal lineages. Here we report an in-depth analysis of pol ν-defective mice and human cells. POLN is very weakly expressed in most tissues, with the highest relative expression in testis. We constructed multiple mouse models for Poln disruption and detected no anatomic abnormalities, alterations in lifespan, or changed causes of mortality. Mice with inactive Poln are fertile and have normal testis morphology. However, pol ν-disrupted mice have a modestly reduced crossover frequency at a meiotic recombination hot spot harboring insertion/deletion polymorphisms. These polymorphisms are suggested to generate a looped-out primer and a hairpin structure during recombination, substrates on which pol ν can operate. Pol ν-defective mice had no alteration in DNA end-joining during immunoglobulin class-switching, in contrast to animals defective in the related DNA polymerase θ (pol θ). We examined the response to DNA crosslinking agents, as purified pol ν has some ability to bypass major groove peptide adducts and residues of DNA crosslink repair. Inactivation of Poln in mouse embryonic fibroblasts did not alter cellular sensitivity to mitomycin C, cisplatin, or aldehydes. Depletion of POLN from human cells with shRNA or siRNA did not change cellular sensitivity to mitomycin C or alter the frequency of mitomycin C-induced radial chromosomes. Our results suggest a function of pol ν in meiotic homologous recombination in processing specific substrates. The restricted and more recent evolutionary appearance of pol ν (in comparison to pol θ) supports such a specialized role.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28570559 PMCID: PMC5472330 DOI: 10.1371/journal.pgen.1006818
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Phenotype analysis.
| Female | Male | |||
|---|---|---|---|---|
| Serum chemistry | WT | KO | WT | KO |
| Body weight (g) | 20.25 ± 2.13 | 23.98 ± 1.39 | 26.41 ± 1.20 | 27.74 ± 0.87 |
| Spleen % | 0.43 ± 0.03 | 0.45 ± 0.04 | 0.39 ± 0.07 | 0.38 ± 0.02 |
| Liver % | 5.08 ± 0.29 | 5.57 ± 0.16 | 5.73 ± 0.46 | 5.40 ± 0.14 |
| Kidney % | 1.29 ± 0.08 | 1.31 ± 0.09 | 1.89 ± 0.21 | 1.68 ± 0.18 |
| Adrenals % | 0.061 ± 0.001 | 0.061 ± 0.008 | 0.023 ± 0.004 | 0.036 ± 0.005 |
| Thymus % | 0.23 ± 0.06 | 0.23 ± 0.04 | 0.17 ± 0.04 | 0.15 ± 0.02 |
| Heart % | 0.53 ± 0.05 | 0.49 ± 0.08 | 0.50 ± 0.05 | 0.49 ± 0.03 |
| Brain % | 1.62 ± 0.08 | 1.48 ± 0.15 | 1.39 ± 0.11 | 1.26 ± 0.02 |
| Testes % | 0.69 ± 0.06 | 0.69 ± 0.04 | ||
| Ovaries % | 0.095 ± 0.022 | 0.099 ± 0.018 | ||
| RBC (x 106/μL) | 9 ± 0.3 | 8.6 ± 1.1 | 8.8 ± 0.3 | 9 ± 0.3 |
| Hemoglobin (g/dL) | 14.6 ± 0.2 | 14.9 ± 0.6 | 13.8 ± 0.6 | 13.7 ± 0.5 |
| Hematocrit (%) | 45 ± 1.2 | 42 ± 1.3 | 41 ± 1.2 | 42 ± 1.7 |
| MCV (fL) | 49.4 ± 0.5 | 48.7 ± 4.7 | 46.4 ± 0.6 | 46.8 ± 0.2 |
| MCH (pg) | 16.2 ± 0.4 | 17.4 ± 2.4 | 15.7 ± 1.0 | 15.3 ± 0.4 |
| MCHC (g/dL) | 32.8 ± 0.5 | 35.6 ± 1.8 | 34 ± 2.2 | 32.7 ± 1.0 |
| RDW (%) | 12.7 ± 0.3 | 12.5 ± 0.1 | 12.6 ± 0.8 | 12.3 ± 0.4 |
| Platelet count (x 103/μL) | 1471 ± 224 | 1610 ± 297 | 1614 ± 170 | 1825 ± 109 |
| MPV (fL) | 8.8 ± 0.9 | 7.7 ± 1.6 | 6.8 ± 0.7 | 6.4 ± 0.2 |
| WBC (x 103/μL) | 6.2 ± 1.0 | 7.9 ± 1.7 | 6.4 ± 1.5 | 6.8 ± 1.4 |
| Seg Neutrophils (%) | 7.3 ± 2.5 | 14.3 ± 5.8 | 15 ± 6.6 | 16 ± 2.7 |
| Band Neutrophils (%) | 0 | 0 | 0 | 0 |
| Lymphocytes (%) | 89 ± 2.7 | 81 ± 4.9 | 80 ± 8.6 | 80 ± 2.5 |
| Monocytes (%) | 1.7 ± 1.2 | 3.3 ± 0.6 | 2.3 ± 3.2 | 2.3 ± 0.6 |
| Eosinophils (%) | 2 ± 3.5 | 1.7 ± 1.5 | 2 ± 1.0 | 2 ± 1.7 |
| Basophils (%) | 0 | 0 | 0.3 ± 0.6 | 0 |
| Metamyelocytes % | 0 | 0 | 0 | 0 |
| ALB (g/dL) | 4.1 ± 0.1 | 4 ± 0.1 | 3.4 ± 0.2 | 3.4 ± 0.2 |
| ALP (u/L) | 126 ± 9.1 | 115 ± 11.5 | 88 ± 15.3 | 83 ± 19.4 |
| ALT (u/L) | 43 ± 2.1 | 60 ± 24.1 | 56 ± 4.9 | 56 ± 1.5 |
| AMY (u/L) | 1252 ± 132 | 1259 ± 41 | 1588 ± 432 | 1410 ± 137 |
| TBIL (mg/dL) | 0.4 ± 0.1 | 0.3 ± 0 | 0.4 ± 0.1 | 0.3 ± 0 |
| BUN (mg/dL) | 19 ± 4.0 | 17 ± 1.5 | 24 ± 0.6 | 23 ± 4.7 |
| CA (mg/dL) | 10.6 ± 0.5 | 11 ± 0.4 | 10.4 ± 0.2 | 10.4 ± 0.5 |
| PHOS (mg/dL) | 15.6 ± 7.6 | 10.1 ± 1.2 | 9.3 ± 1.9 | 9 ± 1.2 |
| CRE (mg/dL) | <0.2 | <0.2 | <0.2 | <0.2 |
| GLU (mg/dL) | 228 ± 7.8 | 243 ± 27.2 | 245 ± 15.6 | 275 ± 44.4 |
| NA (mmol/L) | 156 ± 2.1 | 154 ± 3.1 | 159 ± 2.3 | 157 ± 1.2 |
| K (mmol/L) | >8.5 | 8.5 | >8.5 | 8.4 |
| TP (g/dL) | 5.6 ± 0.1 | 5.9 ± 0.1 | 5.2 ± 0.2 | 5.3 ± 0.1 |
| GLOB (g/dL) | 1.4 ± 0.2 | 1.8 ± 0.1 | 1.8 ± 0.2 | 1.9 ± 0.1 |
| A/G | 2.9 ± 0.3 | 2.2 ± 0.1 | 1.8 ± 0.2 | 1.8 ± 0.2 |
Mean body weights, organ weights, hematology and serum chemistry results for adult 10-week-old Poln (KO) and Poln+/+ (WT) mice of both sexes. RBC: red blood cell count, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: Mean corpuscular hemoglobin concentration, RDW: red cell distribution width, MPV: mean platelet volume, WBC: white blood cell count, ALB: albumin, ALP: alkaline phosphatase, ALT: alanine aminotransferase, AMY: amylase, TBIL: total bilirubin, BUN: blood urea nitrogen, CA: calcium, PHOS: phosphorus, CRE: creatinine, GLU: glucose, NA: sodium, K: potassium, TP: total protein, GLOB: globulin, A/G: albumin/globulin ratio. Mean calculated from 3 mice of each gender and genotype (± SD). Organ weights recorded as percent total body weight.
Percentages of genotypes produced from heterozygous Poln crosses.
| Genotype and gender of mice produced by | |||||
|---|---|---|---|---|---|
| Male | Female | Total | Expected (%) | Observed (%) | |
| 105 | 85 | 190 | 50 | 56 | |
| 35 | 41 | 76 | 25 | 22 | |
| 41 | 32 | 73 | 25 | 22 | |
| 181 | 158 | ||||
| 50 | 50 | ||||
| 53 | 47 | ||||
Incidence of neoplastic findings in PolnΔEx2/ΔEx2 (KO) Poln+/ΔEx2 (HET), and Poln+/+ (WT) mice at end of life.
| Genotype | Number of mice analyzed | HS | TCRBCL | BA Adenoma | BA Carcinoma | Hepatocellular Adenoma | Chromophobe Adenoma | Other Tumor |
|---|---|---|---|---|---|---|---|---|
| KO | 21 | 4 | 10 | 1 | 1 | 2 | 0 | 1 |
| (19) | (48) | (5) | (5) | (10) | (0) | (5) | ||
| HET | 17 | 1 | 5 | 3 | 1 | 0 | 1 | 2 |
| (6) | (29) | (18) | (6) | (0) | (6) | (12) | ||
| WT | 19 | 5 | 6 | 2 | 1 | 1 | 2 | 1 |
| (26) | (32) | (11) | (5) | (5) | (11) | (5) |
Table shows number of mice with indicated tumor type evaluated at end of life (moribund status). There were no significant differences in genotype or tumor type comparisons (Fisher’s exact test). Percentages are shown in parentheses. HS = histiocytic sarcoma; TCRBCL = T-cell-rich B cell lymphoma; BA = bronchioloalveolar.
Tumor multiplicity of PolnΔEx2/ΔEx2, Poln+/ΔEx2, and Poln+/+ mice at end of life.
| Genotype | Number of mice analyzed | Number of mice with tumors | Total tumors | # Tumors per tumor-bearing animal |
|---|---|---|---|---|
| KO | 21 | 15 | 19 | 1.3 |
| (71) | ||||
| HET | 17 | 10 | 16 | 1.6 |
| (59) | ||||
| WT | 19 | 15 | 18 | 1.2 |
| (79) |
The table shows total number of mice analyzed, number of mice with tumors, total number of tumors observed by genotype, percentage of animals analyzed found to have tumors (shown in parentheses) and frequency of tumor occurrence per tumor-bearing animal. There was no significant difference between genotypes in tumor multiplicity (pairwise comparison using Wilcoxon rank sum test).
Incidence of non-neoplastic findings in PolnΔEx2/ΔEx2, Poln+/ΔEx2, and Poln+/+ mice at end of life.
| Genotype | Number of mice analyzed | Pneumonia | Pancreatic Acinar Atrophy | Urinary obstruction | Heart disease | Dermatitis | Renal amyloidosis | Other |
|---|---|---|---|---|---|---|---|---|
| KO | 21 | 4 | 2 | 4 | 5 | 4 | 2 | 3 |
| (19) | (10) | (19) | (24) | (19) | (10) | (14) | ||
| HET | 17 | 8 | 4 | 2 | 3 | 0 | 1 | 7 |
| (47) | (24) | (12) | (18) | (0) | (6) | (41) | ||
| WT | 19 | 7 | 0 | 3 | 4 | 4 | 1 | 5 |
| (37) | (0) | (16) | (21) | (21) | (5) | (26) |
Table shows number of mice with indicated condition evaluated at end of life (moribund status). A comparison between genotypes and conditions by two independent proportions test revealed no significant differences between groups. Percentages are shown in parentheses.
TaqMan primer and probe sets for mouse.
| TaqMan primer | TaqMan probe | |
|---|---|---|
| 5’- GATGTACAAGGATGGTTCCACACA | 5’- AAAGCCTCCTTGGCGCTCA | |
| 5’- GGCTCTGAAGAACTCTTTGCCTTT | 5’- TCCGGGCACTTTTG | |
| 5’- TTTGACCTCCCATACCTCATCTCT | 5’- AAGCGGTCCACCTTTAG | |
| 5’- CTCCCATCGACACCAAAGATCA | 5’- CATAGGCTTTATGAACTTCT |